SEARCH

SEARCH BY CITATION

References

  • 1
    Zelen M. Keynote address on biostatistics and data retrieval. Cancer 1973; 4: 3142.
  • 2
    Lagakos SW. Prognostic factors for survival in inoperable lung cancer. In: StraussMJ, ed. Lung Cancer Clinical Diagnosis and Treatment. New York: Grune & Stratton, 1977; 271280.
  • 3
    Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 2532.
  • 4
    Cohan MH, Selawry OS. Bronchogenic carcinoma: Prognostic factors and criteria of response. In: StaquetM, ed. Cancer Therapy: Prognostic Factors and Criteria of Response. New York: Raven Press, 1975; 185197.
  • 5
    Katlic M, Carter D. Prognostic implications of histology, size and location of primary tumors. In: MuggiaF, RozencweigM, eds. Lung Cancer: Progress in Therapeutic Approach. New York: Raven Press, 1979; 143154.
  • 6
    American Joint Committee for Cancer Staging and End Results Reporting, Task Force on the Lung: Mountain CF, Carr DT, Martini N, Woolner CB, Raventos A. Manual for classification of cancer by site. Chicago, 1977; 5961.
  • 7
    Mountain CF, Carr DT. A system for the clinical staging of lung cancer. Am J Roentgenol 1974; 120: 130138.
  • 8
    Carr DT, Mountain CF. Staging lung cancer. In: StraussMJ, ed. Lung Cancer Clinical Diagnosis and Treatment. New York: Grune & Stratton, 1977; 151161.
  • 9
    Mountain CF, Hermes KE. Management implications of surgical staging studies. In: MuggiaF, RosencweigM, eds. Lung Cancer: Progress in Therapeutic Approach. New York: Raven Press, 1979; 233242.
  • 10
    Martini N, Beattie EJ. Results of surgical treatment in stage I lung cancer. J Thorac Cardiovac Surg 1977; 74: 499505.
  • 11
    Williams DE, Pairolero PC, David CS et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82: 7076.
  • 12
    Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer: Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 1981; 82: 649657.
  • 13
    Oldham RK, Gail MH, Baker MA et al. Immunologic studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 1982; 13: 164173.
  • 14
    Culter SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699712.
  • 15
    Thomas DG, Breslow N, Gart JJ. Trend and hemogeneity analyses of proportions and life table data. Comput Biomed Res 1977; 10. 373381.
  • 16
    Byar DP, Green SB, Dor P et al. A prognostic index for thyroid carcinoma: A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15: 10331041.
  • 17
    Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981; 37: 6778.
  • 18
    Karnofsky DA, Abelmann WH, Craver LF et al. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948; 1: 634656.
  • 19
    McKneally MF, Maver C, Kauel HW. Regional immunotherapy of lung cancer with BCG. Lancet 1976; 21: 377379.
  • 20
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980; 4950.
  • 21
    Concannon JP, Dalbow MH, Hodgson SE et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasmal levels in patients with bronchogenic carcinoma. Cancer 1978; 42: 14771483.
  • 22
    Vincent RG, Chu TM, Lane WW. The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 1979; 44: 685691.